Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New software could sharpen heart mapping

NCT ID NCT03053141

Knowledge-focused Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 4 times

Summary

This study involves 100 adults with heart rhythm problems who are already scheduled for a standard heart mapping procedure. Researchers will test new software features on the mapping system to see how well they work. The goal is to gather feedback to improve future versions of the software, not to directly treat the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2016

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients scheduled for standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 or above, or above legal age and willing and capable of giving informed consent specific to national law 2. Scheduled for standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Exclusion Criteria: 1. Prothrombotic or bleeding tendency due to coagulopathy or blood dyscrasia 2. Inability to tolerate heparin therapy (e.g. heparin induced thrombocytopenia, allergy, etc.) 3. Prosthetic or stenotic valves in the chamber where the intended mapping will occur, or in the path of the catheter access route 4. Active systemic infection or sepsis 5. Hemodynamic instability or shock at baseline precluding ablation in the assessment of the investigator. 6. Presence of intracardiac thrombus, tumor, or other abnormality which precludes catheter introduction 7. Women who are pregnant or lactating 8. Cardiac surgery within the past 90 days 9. Acute myocardial infarction within 3 months 10. Stable/unstable angina or ongoing myocardial ischemia 11. Subjects with an active heart failure decompensation 12. Long QT Syndrome, Brugada Syndrome, or Torsade de Pointes 13. Congenital heart disease with or without corrective surgery that would complicate a mapping procedure 14. Subjects having untreatable allergy to contrast media 15. Vascular pathology or tortuosity precluding standard vascular access techniques 16. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the patient is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance should be brought to the attention of the sponsor to determine eligibility.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial tachyarrhythmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial tachycardia cardiac rhythm disease ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac arrythmias

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cardiovascular Specialists of New England Research Foundation

    RECRUITING

    Londonderry, New Hampshire, 03053, United States

  • Catholic Medical Center

    COMPLETED

    Manchester, New Hampshire, 03102, United States

  • Centre Hospitalier Princesse Grace

    COMPLETED

    Monaco, 98000, Monaco

  • Fondazione Centro San Raffaele

    COMPLETED

    Milan, MI, 20132, Italy

  • Lahey Clinic, Inc.

    COMPLETED

    Burlington, Massachusetts, 01805, United States

  • St. Lukes Idaho Cardiology Associates

    COMPLETED

    Boise, Idaho, 83712, United States

  • University of Alabama at Birmingham

    COMPLETED

    Birmingham, Alabama, 35233, United States

  • Valley Hospital

    COMPLETED

    Ridgewood, New Jersey, 07450-2736, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.